Hiraoka, Atsushi
Tanizawa, Yoshinori http://orcid.org/0000-0002-5014-2483
Huang, Yu-Jing
Cai, Zhihong
Sakaguchi, Sachi
Funding for this research was provided by:
Eli Lilly Japan
Article History
Accepted: 10 March 2021
First Online: 1 April 2021
Declarations
:
: This study was sponsored by Eli Lilly Japan K.K., manufacturer/licensee of ramucirumab, which was involved in the study design, data collection, data analysis, and preparation of the manuscript. The publication charges were paid for by Eli Lilly Japan K.K.
: AH has received speaker fees from Eisai, Bayer, and Otsuka. YT, Y-JH, ZC, and SS are employees and/or minor shareholders of Eli Lilly Japan K.K.
: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Pharmacoepidemiology Practices. This observational study analyzed de-identified data from an administrative claims database; therefore, the study was exempt from ethical review and informed consent was not required.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors participated in the interpretation of study results, and in the drafting, critical revision, and approval of the final version of the manuscript. YT and ZC conducted the statistical analysis.
: The data in this study are commercially available from Medical Data Vision Co., Ltd and were used under licence. As restrictions apply to the availability of these data, they are not publicly available. Data can be made available from Medical Data Vision Co., Ltd upon request.